We further investigated the biological impact of co-treatment with ralimetinib and CHTs or trametinib on patient-derived CRC-SC fate by analyzing Ki67 expression and annexin V staining by flow cytometry. The gene discussed is ANXA5; the disease is colorectal carcinoma.